[1]
Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - A Systematic review and meta-analysis. PLoS One 2016; 11(7): e0158765.
[2]
Simeoni M, Cianfrone P, Comi N, et al. Is it feasible to improve
the duration and the efficiency of Ramipril anti-proteinuric response?. G Ital Nefrol 2015; 32(1), pii: gin/32.
[3]
D’Onofrio G, Simeoni M, Rizza P, et al. Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. Ren Fail 2017; 39(1): 45-53.
[4]
Tomino Y. Diagnosis and treatment of patients with IgA nephropathy in Japan. Kidney Res Clin Pract 2016; 35(4): 197-203.
[5]
Cheng J, Zhang X, Zhang W, et al. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: A meta-analysis of randomized controlled trials. Am J Nephrol 2009; 30(4): 315-22.
[6]
Pozzi C. Pro: STOP immunosuppression in IgA nephropathy? Nephrology, dialysis, transplantation : Official publication of the European Dialysis and Transplant Association - European Renal Association 2016; 31(11): 1766-70.
[7]
Coppo R, Peruzzi L, Amore A, et al. IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol JASN 2007; 18(6): 1880-8.
[8]
Cianfrone P, Simeoni M, Comi N, et al. How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT-a prospective cohort study. J Nephrol 2017; 30(1): 95-102.
[9]
Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109(11): 1417-27.
[10]
Prieto-Carrasquero MC, Kobori H, et al. AT1 receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Am J Physiol Renal Physiol 2005; 289(3): F632-7.
[11]
Danser AH, Derkx FH, Schalekamp MA, et al. Determinants of interindividual variation of renin and prorenin concentrations: Evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998; 16(6): 853-62.
[12]
Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007; 72(1): 45-52.
[13]
Advani A, Kelly DJ, Cox AJ, et al. The (Pro)renin receptor: Site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension 2009; 54(2): 261-9.
[14]
Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996; 50(6): 1897-903.
[15]
Huang Y, Border WA, Noble NA. Functional renin receptors in renal mesangial cells. Curr Hypertens Rep 2007; 9(2): 133-9.
[16]
Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69(1): 105-13.
[17]
Kaneshiro Y, Ichihara A, Sakoda M, et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol: JASN 2007; 18(6): 1789-95.
[18]
Sanoski CA. Aliskiren: An oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy 2009; 29(2): 193-212.
[19]
Riccioni G. Aliskiren in the treatment of hypertension and organ damage. Cardiovas Therapeut 2011; 29(1): 77-87.
[20]
Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52(1): 130-6.
[21]
Simeoni M, Nicotera R, Colao M, et al. Direct inhibition of plasmatic renin activity with aliskiren: A promising but under-investigated therapeutic option for non-diabetic glomerulonephritis. Int Urol Nephrol 2016; 48(2): 229-37.
[22]
Ferri N, Greco CM, Maiocchi G, Corsini A. Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. J Renin Angiotensin Aldosterone Syst: JRAAS 2011; 12(4): 469-74.
[23]
McMurray JJ, Abraham WT, Dickstein K, et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012; 14(4): 341-3.
[24]
Zheng SL, Roddick AJ, Ayis S. Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients. Diab Vasc Dis Res 2017; 14(5): 400-6.
[25]
Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50(11): 2398-404.
[26]
Lizakowski S, Tylicki L, Rutkowski B. Direct renin inhibition--a promising strategy for renal protection? Med Sci Monit 2013; 19: 451-7.
[27]
Gross O, Girgert R, Rubel D, et al. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens 2011; 24(3): 355-61.
[28]
Tang SC, Lin M, Tam S, et al. Aliskiren combined with losartan in immunoglobulin A nephropathy: An open-labeled pilot study. Nephrol Dial Transplant 2012; 27(2): 613-8.
[29]
Wu MT, Tung SC, Hsu KT, Lee CT. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: an open-label prospective trial. J Renin Angiotensin Aldosterone Syst: JRAAS 2014; 15(3): 271-7.
[30]
Moriyama T, Tsuruta Y, Kojima C, et al. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Int Urol Nephrol 2012; 44(3): 841-5.
[31]
Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47(5): 751-60.
[32]
Woo KT, Choong HL, Wong KS, et al. Aliskiren and losartan trial in non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Sys: JRAAS 2014; 15(4): 515-22.
[33]
Szeto CC, Kwan BC, Chow KM, Leung CB, Li PK. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study. PLoS One 2013; 8(5): e62736.
[34]
Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int 2017; 91(5): 1014-21.
[35]
Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353(9156): 883-7.
[36]
Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372(9638): 547-53.
[37]
Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 2017; 91(3): 683-90.
[38]
Ahmed A, Jorna T, Bhandari S. Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease? Nephron 2016; 133(3): 147-58.
[39]
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289(19): 2560-72.
[40]
Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123(10): 1098-107.
[41]
Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32(10): 1873-9.
43
4